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Summary In this study cell lines have been used to determine the level of correlation between three assays
which are in use for in vitro prediction of human tumour chemosensitivity. The methods which were
compared included a clonogenic assay, a monolayer assay and a short-term biochemical assay. The results
indicated that the monolayer and clonogenic assays were either directly comparable or could be made
comparable by reducing the drug exposure time in the monolayer assay. The biochemical assay also gave
comparable results for 3 of the 5 drugs tested. It was concluded that although the 3 assays did not produce
identical dose-response curves, the assays were equally valid when used for predictive testing because selection
of cut-off points which were based on retrospective correlations between in vitro sensitivity data and response
data, as established by other authors, compensated for differences in sensitivity between the assays.
Interest in the use of in vitro predictive tests for the
determination of chemosensitivity of human
tumours has escalated in recent years and from
1970 there have been numerous publications in
which different methodologies have been described.
The methods can be simply categorised into (i)
assays using short-term cultures of cell suspensions
(e.g. Volm et al., 1979; Group for Sensitivity
Testing (KSST), 1981; Sanfilippo et al., 1981) (ii)
assays using cell monolayers (e.g. Mitchell et al.,
1972; Holmes & Little, 1974; Berry et al., 1975;
Shrivastav et al., 1980; Kornblith et al., 1981;
Wilson & Neal, 1981) (iii) assays which measure
clonogenic cell survival (e.g. Hamburger et al.,
1978; Salmon et al., 1978; Rosenblum et al., 1978;
Sarosdy et al., 1982). Irrespective of the type of
assay used, good correlation between in vitro results
and response of individual patients has been
reported by the majority of groups, particularly in
the accurate prediction of clinical resistance (e.g.
Wheeler et al., 1974; Group for Sensitivity Testing
(KSST) 1981; Salmon et al., 1978).
Advantages and disadvantages are associated
with each assay, and the variety of methods used
indicates the dilemma of those in the field of in
vitro predictive testing, as to which assay is the
most relevant. That good correlation between
clinical results and in vitro results are obtained
regardless of the methodology indicates that the
assays should give the same results for the same
tumour specimen, but in one study in which
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different methodologies were compared using T,
lymphoma cells, the only reliable dose-dependent
index of drug effect was found to be colony
formation (Roper & Drewinko, 1976). No recent
studies have been carried out in which different
methodologies which are presently in use for
chemosensitivity testing of human tumours have
been evaluated for comparability of assays in terms
of their ability to predict the same chemosensitivity
pattern for the same tumour. We have therefore
chosen to compare three assays which are in
current use: these are a short-term biochemical
assay (B) used extensively in W. Germany (Volm et
al., 1974; KSST, 1981), a monolayer assay using
microtitration plates (M) (Freshney et al., 1975;
Wilson & Neal, 1981) and a clonogenic assay (C),
which is basically as described by Hamburger
(Hamburger et al., 1978). Assay characteristics are
compared in Table I. Preliminary results are
presented using cell lines which have provided us
with a continuous source of material for replicate
studies and have also eliminated complications
introduced by the presence of normal cells.
Materials and methods
Cell lines
The cell lines used in these studies were T13-adeno
2 transformed rat embryo fibroblasts (Harwood,
1975) and MCF-7-human breast adenocarcinoma
cells (Soule et al., 1973). Cells were cultured in
Dulbecco's modification of Eagle's medium (DME)
supplemented with 10% foetal calf serum, insulin,
glutamine, sodium pyruvate and antibiotics. Both
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cell lines were sub-cultured at weekly intervals and
early confluency cultures were used for all assays.
Drugs
The following drugs were tested: Adriamycin-ADM
(Farmitalia Carlo Erba Ltd.), Cis Platinum II
diammine dichloride-CIS (N.C.I. Bethesda),
Bleomycin (BLM, Lundbeck Ltd.), 5-Fluorouracil
(FU, Roche Ltd.) and Cytosine Arabinoside (CYT,
UpJohn Ltd.). ADM was tested at 2.0, 0.2 and
0.02yjgml-1 and all other drugs at 0.1, 1.0 and
10pgml-1; solutions were made up immediately
before use using either growth medium (for the
monolayer assay) or Hanks' Balanced Salt Solution
with 10% foetal calf serum (for the biochemical
and clonogenic assays).
Assays
Biochemical assay (B) Cells were incubated at a
final concentration of 105 cellsml-1 per tube using
3 replicates. Incubations were carried out at 37°C in
a water shaker bath for 3h and in the final h
2.5pCiml-' of a radiolabelled nucleotide was
added to each tube; (6-[3H]-uridine, 22 Cimmol1
was used for ADM, methyl-[3H]-thymidine,
5Cimmol-1 for CIS, BLM and CYT, and 6-[3H]-
deoxyuridine, 25Cimmol ' for FU. All
radionucleotides were obtained from Amersham
International, PLC). After incubation cells were
immediately treated with ice cold 5%
trichloroacetic acid followed by methanol, and the
amount of radioactivity incorporated into the acid
insoluble residue was determined using liquid
Table I Characteristics of the three assays
Cyto- Dura-
Duration toxicity ation
Culture ofdrug Recovery inhibition of
Assay method exposure period of: assay
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M: Monolayer assay; C:
scintillation counting. Results were expressed as a
percentage of the control nucleotide incorporation
for each drug and drug concentration tested.
Monolayer assay (M) Drug solutions were added
24h after tumour cells had been plated at 2 x104
viable cells/well into 96-well flat-bottomed micro-
titration plates (Nunc), and incubations were
carried out at 37°C in an atmosphere of 95%
air/5% CO2. In the routine procedure cells were
exposed to drugs for 48h, washed with PBS and
allowed a 24h recovery period in fresh growth
medium (=M48). Because there were differences in
exposure time between the 3 routine assays, a
reduced exposure time was also used in the
monolayer assay to determine the effect of this
variable on assay comparability. Thus in some
assays cells were exposed to drugs for 3h, washed
in PBS and allowed a 69h recovery period in
growth medium (=M3). At the end of the in-
cubation period L-4-5-[3H]-Leucine (56Cimmol. -1
Amersham International, PLC) was added to a
final cdncentration of 2pCiml-' per well and the
cells were incubated for a further 3h. The amount
of [3H] Leucine incorporated into protein was
determined using previously described methods
(Freshney, 1975) and results were expressed as a
percentage of control leucine incorporation.
Replicates of three wells per test condition were
used.
Clonogenic assay (C) Single cells were incubated at
a final cell concentration of 105 viable cellsml-1 at
37°C in a water shaker bath for 1 h with the
various drugs, using duplicate tubes for each test
condition. At the end of the incubation period cells
were washed with Hanks' BSS containing 10%
foetal calf serum and resuspended in 2ml of 0.3%
agar in growth medium. Cells were immediately
plated out in 1 ml aliquots onto previously prepared
bases of 0.5% agar in growth medium in 35mm
petri dishes (Nunc), to give a final plated cell
number of 5 x 104 cells per dish. Replicates of 4
were obtained for each test condition. Plates were
incubated at 37°C in a humidified atmosphere
containing 95% air/5% C02, and were scored for
colonies (aggregates of .50 cells) after 7-10 days.
Results were expressed as a percentage of control
colony counts.
Analysis ofresults
The s.e. of the test mean was expressed as a
percentage of the control mean, and used to
indicate the within-assay variation. Values were
routinely less than + 10% for test and control
plants in the monolayer assay, whilst for the bio-
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were routinely obtained. Higher values did
sometimes occur, the incidence being the greatest in
the latter two assays. Results were generally
obtained for at least 2 experiments for each drug
and assay.
Classification ofchemosensitivity ofcell lines
The ultimate objective of any predictive test is the
classification of a tumour cell population as
sensitive or resistant to a particular drug. The 3
assays in this study have all been used to
investigate human tumour material and cut-off
points have been defined for each assay by the
original groups, which were based on correlations
between in vitro results and clinical response data.
These same cut-off points have therefore been
selected for sensitivity classification of the cell lines
since their validity has been described elsewhere.
For B, a cut-off point of <65% of control at
2jugml-1 of ADM was used to define the cell lines
as sensitive (cf. KSST, 1981). Cut-off points for the
other drugs have not been defined and therefore for
the purpose of this study 65% has been arbitrarily
selected for CYT, FU, BLM and CIS. For M a
cut-off point of <50% of control was used to
define sensitivity at 1 and 10 gml-P (Wilson &
Neal, 1981). For C, areas under the curve were
originally used to define sensitivity (Salmon et al.,
1978) but other groups using the same method have
used <30% of control (Ozolls et al., 1980), and for
comparison between assays the latter has been
chosen, again at 1 and 10 igml-1. When results of
duplicate experiments differed, the cell line was
classed as border-line sensitivity (R/S).
Results
Under the conditions used, plating efficiencies of
0.8-1% were obtained for both cell lines, giving
400-500 colonies per control plate. The doubling
times in monolayer for each cell line were also
similar at -24h. The results of duplicate
experiments obtained with both cell lines for all
drugs and assays are shown in Figures 1-3 and
Table II.
Adriamycin
Results obtained with ADM are shown in Figure 1
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Figure 1 A comparison of dose response curves obtained with adriamycin for T13 and MCF 7 cells.
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Table II Comparisons of in vitro sensitivity predictions
from three assays
ADM CIs FU BLM CYT
T13 MCF 7 T13 MCF 7 T13 T13 T13
0.2 2.0 0.2 2.0 1.0 10 1.0 10 1.0 10 1.0 10 1.0 10
M48 R S R S R S R R/S S S S S S S
M3 R S -- R S -- R S S S R R/S
C R S R S R S R R/S R R/S R S R R/S
B S S R/SR/S R R R R R R S S
Drug concentrations are in Mgml-l.
S and R: See Materials and methods for explanation of
cut-offpoints.
ADM at 2pgml-' for both cell lines, and were
therefore directly comparable. Reduction of the
drug exposure time in M to 3 h (M3) did not affect
the sensitivity classification and the different assays
therefore correlated despite the differences in
exposure time.
Cis platinum
Results obtained with CIS are shown in Figure 2
and Table II. At 1 pgml-1 all assays predicted
resistance for both cell lines, with the exception of
B, which predicted borderline sensitivity of Tl3
cells (R/S). At lOpgml-', M48, M3 and C assays
correlated in predicting sensitivity of T13 cells
whilst B again predicted borderline sensitivity.
Although C showed extreme sensitivity of T13 at
10ygml-1, M3 showed only borderline sensitivity.
Thus M48 and C showed better correlation despite
the differences in exposure time. At 0Mgml-' M48
and C both predicted border-line sensitivity of
MCF 7 and B predicted resistance. All 3 assays
therefore demonstrated a greater resistance of MCF
7 cells to CIS.
5-fluorouracil, Bleomycin, cytosine arabinoside
Results for FU, BLM, and CYT are shown in
Figure 3 and Table II for T13 cells only. Disparity
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Figure 3 A comparison of dose response curves obtained with 5-fluorouracil, cytosine arabinoside, and
bleomycin for T13 cells. See Figure 1 for symbols.
which were attributable to the differences in
exposure time. The routine monolayer assay
predicted sensitivity to FU at 1 and 10pgml-P
whilst C predicted resistance at 1 gml-' and
borderline sensitivity at 10ygml-. In M3
resistance was also predicted at lygml-' but the
cells were still sensitive at 10ygml-'. Reduction of
exposure times to comparable levels between assays
did therefore contribute towards eliminating
differences between C and M. The biochemical
assay indicated resistance to FU at both
concentration levels. When BLM was tested B
actually predicted sensitivity at the lowest concen-
tration tested, but at the two higher concentrations
the cell line was resistant according to the
sensitivity classification for this assay. In M48 and
M3 cells were sensitive at 1 and 10pgml-1 with
comparable dose-response curves despite the
differences in exposure time, whilst in C cells were
resistant to l gml-1, but sensitive to 10pgml-'.
Thus, as for FU, C and M were comparable at
lOpgml-'.
With CYT C predicted borderline sensitivity at
lOpgml-', which correlated with M3. M48 did not
correlate with C since it predicted sensitivity both
at 1 and 10pgml-P. It did, however, correlate with
B which also predicted sensitivity at 1 and
l10gml-.
Discussion
In this investigation the degree of comparability
between three assays routinely used for predicting
the chemosensitivity of human tumours was found
to be dependent on the drug and duration of drug
exposure when cell lines were used. With all drugs
tested the monolayer and clonogenic assays were
either comparable despite the differences in drug
exposure time or could be made comparable by
reducing the exposure time in monolayer assay.
This indicates that the total proliferating cell
population, the chemosensitivity of which is
determined in M, shares the same chemosensitivity
profile as that of the clonogenic population. It is
therefore feasible to suggest that the monolayer
assay shares the biological validity of the clono-
genic assay. The inability of normal cells to
proliferate in soft agar is a factor which has
particularly recommended the clonogenic assay for
chemosensitivity testing of human tumours, because
for many tumours stromal cell overgrowth
precludes the use of a monolayer assay. However,
the relevance of the clonogenic assay in in vitro
predictive testing has been questioned because
several groups have failed to repeat the original
findings (Rupniak & Hill, 1980; Bertoncello et al.,
1982; Agrez et al., 1982) and the veryjow plating
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efficiencies which have been obtained with human
tumours reduces the success rate in obtaining
chemosensitivity results. The results reported here
lead to the conclusion that, at least for tumours in
which a pure population of tumour cells can be
obtained the validity of the monolayer assay
equates with that of the clonogenic assay. A recent
publication reports good correlation between
chemosensitivity results obtained using a monolayer
cloning assay and the monolayer/microtitration
plate assay with human astrocytomas (Morgan et
al., 1983) and therefore indicates that the findings
of the present study may also be relevant for
primary human tumours.
Although the biochemical assay was less sensitive
than the other two assays, the higher cut-off point
compensated for this and the assay was able to
predict sensitivity to ADM which confirms the
original findings (KSST, 1981), and also to CYT,
CIS and possibly BLM. More recent results have
shown that the low levels of inhibition which are
common to this assay are a result of technical
artefacts which can be eliminated by changing the
methodology (Wilson et al., 1983) and it is possible
therefore that this assay could be equally valid for
predictive testing.
Considering the differences in methodologies
between the assays, it is hardly surprising that the
dose-response curves were not comparable for some
of the drugs. The results do indicate however, that
differences between the assays are automatically
compensated for when cut-off points which are
based on retrospective correlations between results
obtained with the particular assay using human
tumour material and clinical response data are used
to define sensitivity. Although this study has not
used primary tumour material it is valid to
extrapolate the findings to this situation since the
assays have all been proved in a clinical context. In
conclusion therefore, provided the assay produces a
dose-related depression of the chosen end-point the
methodology is irrelevant if retrospective
correlations between in vitro data and response data
are made for a number of specimens, in order to
define sensitivity.
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